IM-PROVE II

IM-PROVE II is an investigational combination regimen being developed by Arbutus Biopharma in collaboration with Barinthus Biotherapeutics (formerly Vaccitech) for the treatment of chronic hepatitis B virus (cHBV) infection. The regimen is designed to promote functional HBV control and consists of imdusiran (AB-729), a GalNAc-conjugated RNA interference (RNAi) therapeutic that suppresses hepatitis B surface antigen (HBsAg) and other viral proteins; VTP-300, an antigen-specific T-cell stimulating immunotherapeutic vaccine; and standard-of-care nucleos(t)ide analogue (NA) therapy, with or without the addition of low-dose nivolumab, an anti-PD-1 monoclonal antibody. By combining viral antigen suppression with immune-boosting agents, the regimen aims to reawaken the host's HBV-specific immune response to achieve a functional cure.

Other names

AB-729 + VTP-300 + NAAB-729 + VTP-300 + NA + nivolumabAB-729 + VTP-300 + NA +/- nivolumabAB-729 + VTP-300 + nucleos(t)ide analogueAB-729 + VTP-300 + nucleos(t)ide analogue + nivolumabAB-729 + VTP-300 + nucleos(t)ide analogue +/- nivolumabimdusiran + VTP-300 + NAimdusiran + VTP-300 + NA + nivolumabimdusiran + VTP-300 + NA +/- nivolumabimdusiran + VTP-300 + nucleos(t)ide analogueimdusiran + VTP-300 + nucleos(t)ide analogue + nivolumabimdusiran + VTP-300 + nucleos(t)ide analogue +/- nivolumab